AUTO8
Relapsed/Refractory Multiple Myeloma
Key Facts
About Autolus Therapeutics
Autolus Therapeutics is a UK-based biotech focused on developing advanced, programmed CAR T-cell therapies with the goal of delivering life-changing benefits to patients. Its most advanced asset, obecabtagene autoleucel (obe-cel), has demonstrated compelling clinical data in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and is progressing through late-stage development. The company's strategy hinges on its proprietary technology platform to create differentiated products, vertical integration for manufacturing control, and expansion into solid tumors and autoimmune diseases to build a diversified pipeline.
View full company profileTherapeutic Areas
Other Relapsed/Refractory Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Aplidin (plitidepsin) | PharmaMar | Approved (Conditional - AU) |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Development |
| inobrodib + Pd (InoPd) | CellCentric | Phase 1/2 |
| TECVAYLI + DARZALEX FASPRO | Johnson and Johnson Innovative Medicine | Approved |
| HDP-101 | Heidelberg Pharma | Phase 1/2a |
| CT053 | CARsgen Therapeutics | Phase 1b/2 |
| P-BCMA-ALLO1 | Poseida Therapeutics | Phase 1 |
| ABBV-383 | AbbVie | Phase 1 |
| Blenrep (belantamab mafodotin) | GSK plc | Phase III |
| bri-cel (BAY 2413334) | Bayer | Phase I |
| Ciltacabtagene autoleucel (Carvykti) | Genscript Biotech | Approved / Phase 3 |
| CAR-T Cell Therapy | Dr. Reddy's Laboratories | Discovery/Development |